Protein Biomarker Detection with Olink Proteomics


Leveraging Olink Proteomics® Proximity Extension Assay (PEA) technology, protein biomarker detection services from Azenta Life Sciences enable detection and quantification of circulating proteins to provide an in-depth, biological understanding of disease and drug response. Unlike traditional methods, this approach enables high-throughput, simultaneous analysis of proteins with high specificity and sensitivity using minimal sample amounts. Processing is available for research use only (RUO) or can be performed in our CAP-accredited, CLIA-certified laboratory for clinical applications. 

For a multiomics approach, this proteomics service can be combined with Azenta’s genomic and transcriptomic solutions to provide a comprehensive understanding of molecular changes contributing to development, disease, and drug response in clinical trials.



Enhance and increase your biomarker detection using Olink technology

Streamline your discovery and clinical workflows with multiomics solutions you can trust.



Drug Target Identification & pQTLS


Biomarker Analysis & Screening


Exploratory Endpoints in Clinical Trials


Protein Response Validation in Clinical Trials


Genomics, transcriptomics, epigenomics, and proteomics individually provide unique and crucial insight into the inner workings of human cells. Collectively, these multiomic tools can provide detailed insights into relationships and patterns to help you accelerate and expand your search for drug targets.


Uniquely Scalable Proteomics

Olink platforms scale from highplex product Olink Explore 3072, to midplex Olink Target 48 and Olink Target 96 down to customized lowplex Olink Focus and Olink Flex.

Clinical-Icon  Olink Explore 3072/384  Olink Target 96  Olink Target 48 Olink Flex
Comprised of eight 384-plex human disease focused panels, Olink Explore is both flexible and scalable; you may run the entire library or focus on one or more of the 384-plex panels. With Olink Target 96, choose from fifteen carefully designed panels built for specific areas of human disease and key biological processes. For researchers working with mouse models, Target 96 Mouse Exploratory is also available.  One of the broadest human cytokine inflammation panels available, Olink Target 48 allows for analysis of proteins with the highest relevance for investigation of inflammatory processes and diseases to support clinical trials.

With Olink’s made-to-order product, Olink Flex, researchers can select and combine targets for up to 21 human proteins in one biomarker panel. Choose from over 200 inflammation-related human proteins in a comprehensive mix-and-match library.

These panels are organized into four disease areas:

  • Cardiometabolic
  • Inflammation
  • Neurology
  • Oncology

Disease area:

  • Cardiovascular Disease II, Cardiovascular Disease III, Oncology, Oncology III, Neurology, Inflammation, Immuno-oncology

Biological process:

  • Cardiometabolic, Cell regulation, Neuro-exploratory, Immune Response, Development, Metabolism, Organ Damage

Use the Target 48 cytokine panel to elucidate:

  • In vitro therapeutic effects on the number of cytokines produced
  • Candidate biomarkers for predicting response and/or toxicity
  • The immune system mechanism of action by coupling Target 48 cytokine panel with gene expression (RNA) data 
  • Immunogenicity induced by your agent in vivo

Choose and combine pre-validated inflammation focused assays from Olink's extensive biomarker library. The assays have 99% combinability and maintains the quality, performance, specificity, and sensitivity associated with standard Olink panels. The data is reported in absolute (pg/mL) or relative (NPX) quantification.




Standard Deliverables

  • Absolute quantification in pg/ml (Olink Target 48 only)
  • Data in Normalized Protein Expression (NPX) format for relative quantification
  • Certificate of Analysis showing quality details – internal and external controls are included throughout the workflow to ensure data quality

Advanced Analysis

(In addition to standard deliverables)

  • Data visualization: Provides a principal component analysis and heatmap to visualize sample distribution and protein expression – results are illustrated from differential expression analysis in both table and interactive-graphic formats
  • Statistical analysis: Includes differentially expressed protein analysis – input will be absolute quantification value for Olink Target 48 or NPX value for Olink Target 96

Custom bioinformatics analysis and reports are available. Please contact us about how we can customize your analysis to answer your biological question.


Features and Benefits


  • Building

    Sample and Material Management

    Offering sample sourcing, storage, and transport of your samples
  • Building

    Fast Turnaround

    Starting at just 10 business days for expedited projects
  • Building

    Trusted Partner

    By all top 20 biopharma companies
Processing available in our CLIA/CAP laboratory for clinical applications
As little as 1 µL needed for analysis, with 40 µL recommended for sample submission
Dual-recognition of two antibodies and DNA barcoding unique to each protein enables high specificity of protein detection – no readout of cross-reactivity
High sensitivity for protein detection, similar to ELISA or better
Increased precision (average intra %CV <10% and inter %CV <20%) across multiplex and midplex assays
Dynamic range spanning more than 10 logs, which makes it ideal for the study of the plasma proteome

Get Rewarded for Your Referrals

Unlock 20% off your next genomics order*

*Terms & conditions apply

Blog | Comparing Mass Spectrometry, ELISA, and Olink for Proteomics

The field of proteomics has evolved significantly in the last decade, with several technologies now available to assay protein biomarkers in clinical studies. In this article, we compare three popular approaches for proteomics - mass spectrometry, ELISA, and the Olink® Proximity Extension Assay (PEA) - and highlight their strengths and limitations.

Tech Note | Proteomic Biomarker Discovery to Support Clinical Trials

Traditionally preclinical exploratory research and clinical trial biomarker detection and measurement have been restricted to a few indicators measured by mass spectrometry and ELISA. Discover how Azenta has implemented fully validated protein biomarker discovery services using the Olink® Proximity Extension Assay (PEA) technology capable of detecting and measuring hundreds to thousands of proteins simultaneously.

Tech Note | High-Plex Exploratory Biomarker Discovery to Support Proteomics and Multiomics Research

The development of novel strategies for mid-to high-plex protein detection and quantification enables greater utilization of protein biomarkers across the drug discovery and development process. Using Olink® Proximity Extension Assay (PEA) technology, Azenta has deployed fully validated protein biomarker discovery services for up to 1 million data points per experiment with comparable sensitivity to traditional methods and utilization of lower sample amounts.

Blog | How Olink technology is revolutionizing proteomics and multiomics

Current proteomics technologies often present limitations in terms of throughput, specificity, and cost. However, new innovations, such as Olink Proteomics’ PEA technology, are overcoming these challenges by enabling hundreds to thousands of proteins to be measured in a single sample. In this blog, discover how Azenta is leveraging PEA technology for protein biomarker discovery, its applications, and how it can complement genomics data to accelerate drug development.

Webinar | Precision Proteomics: How to Enable Biomarker Identification in Health and Disease

Hear directly from Olink Proteomics about precision protein analysis as a tool to improve health outcomes for patients with cancer, inflammatory, or age-related diseases. Take this chance to discover how you can bring your protein biomarker discovery to the next level with Olink PEA technology.

Webinar | Do More with Less: Harnessing the Power of Multiomics from a Single Sample

The -omics era has greatly expanded the repertoire of approaches available for researchers and clinicians to unravel the complexities underpinning human health. In this recording from the Azenta Life Sciences Breakfast Talk at ASHG 2022, Dr. Andrea O’Hara presents a workflow to rapidly produce a diverse set of multiomics results, including genomics, epigenomics, transcriptomics, and proteomics, from a single blood draw. 

Poster | A Demonstrated Workflow to Unleash the Multiomic Potential of a Single Blood Draw

The multiomics era has greatly expanded the repertoire of approaches available for researchers and clinicians to unravel the complexity underpinning human health. Explore how the single blood draw multiomics workflow from Azenta Life Sciences can drive more significant insights and innovation in human health applications.


Azenta is a certified service provider for Illumina and other cutting-edge NGS platforms. For information on our NGS platforms, as well as recommended configurations of your projects, please visit the NGS Platforms page. Azenta does not guarantee data output or quality for sequencing only projects. 

How To Order

Email | Phone 1-877-436-3949, Ext. 1